Valneva Provides Update on IXIARO® Supply Contract with U.S. Department of Defense


Saint Herblain (France), August 18, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) a specialty vaccine company, today announced that the U.S. Department of Defense (DoD) has decided not to exercise the second option year of the contract1 to supply Valneva’s Japanese encephalitis (JE) vaccine IXIARO®.

Read more:
Valneva Provides Update on IXIARO® Supply Contract with U.S. Department of Defense

Related Posts